Swiss National Bank Sells 1,400 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Swiss National Bank lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 0.5% during the third quarter, Holdings Channel.com reports. The firm owned 256,600 shares of the company’s stock after selling 1,400 shares during the quarter. Swiss National Bank’s holdings in Ionis Pharmaceuticals were worth $10,279,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of IONS. Mather Group LLC. boosted its stake in shares of Ionis Pharmaceuticals by 35.8% during the second quarter. Mather Group LLC. now owns 911 shares of the company’s stock valued at $39,000 after purchasing an additional 240 shares during the period. Vanguard Personalized Indexing Management LLC boosted its position in Ionis Pharmaceuticals by 3.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock valued at $363,000 after buying an additional 261 shares during the period. Nicollet Investment Management Inc. grew its holdings in Ionis Pharmaceuticals by 1.5% in the 3rd quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock worth $817,000 after acquiring an additional 294 shares during the last quarter. Amalgamated Bank grew its holdings in Ionis Pharmaceuticals by 3.1% in the 3rd quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock worth $399,000 after acquiring an additional 300 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after acquiring an additional 303 shares during the period. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Price Performance

NASDAQ IONS opened at $34.01 on Monday. The business’s fifty day moving average is $38.70 and its 200 day moving average is $42.49. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $33.33 and a fifty-two week high of $54.44. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91. The company has a market capitalization of $5.37 billion, a PE ratio of -13.94 and a beta of 0.39.

Insider Activity

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 6,630 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the completion of the sale, the chief executive officer now owns 167,393 shares in the company, valued at approximately $6,369,303.65. This represents a 3.81 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Eric Swayze sold 1,194 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the transaction, the executive vice president now owns 33,713 shares in the company, valued at $1,278,396.96. The trade was a 3.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,197 shares of company stock valued at $315,310 in the last ninety days. Corporate insiders own 2.71% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IONS. JPMorgan Chase & Co. boosted their price target on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Monday, August 26th. Needham & Company LLC restated a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, November 7th. Wells Fargo & Company cut their price target on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. The Goldman Sachs Group upped their price objective on shares of Ionis Pharmaceuticals from $33.00 to $37.00 and gave the stock a “sell” rating in a report on Friday, August 2nd. Finally, StockNews.com lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $60.65.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.